In March 2018 Congress passed an omnibus bill that finalized Fiscal Year 2018 appropriations. Guillain-Barré Syndrome was again listed as a condition eligible for study! Now is the time to begin applications for available grants. Below is more detailed information regarding applications and possible awards.Read More about Attention Researchers! GBS Deemed Eligible for Research Studies through Department of Defense Peer Review
On June 10, 2018 the GBS|CIDP Foundation International will be holding its 5th Annual New Jersey Walk & Roll. The event will be chaired by local resident, and Foundation volunteer, Susan Salzmann. Recently we had the pleasure of sitting down with Susan as she shared the complex story of her husband’s personal journey with CIDP….Read More about A Life and Legacy Dedicated to Research
The Food and Drug Administration granted marketing clearance Friday for Hizentra, a treatment for chronic inflammatory demyelinating polyneuropathy (CIDP) developed by CSL Behring. Lisa Butler, executive director of the GBS/CIDP Foundation International, said “The approval of Hizentra offers patients who were once burdened by traveling to the infusion center or hospital the flexibility to self-administer their treatment at…Read More about FDA approves CSL Behring treatment for CIDP
The GBS|CIDP Walk & Roll program is a great opportunity to raise awareness, build a local support network, and get involved with GBS|CIDP community. This year we are pleased to announce that funds raised through the Walk & Roll program will be used to support research studies focused on the treatment and diagnosis for GBS|CIDP…Read More about Where Do Walk Donations Go? Research!
(#1) Title of the project: Enhance Peripheral Nerve Repair by Modulating Macrophage Subsets Investigator: Gang Zhang, M.D; Ph.D Assistant Professor of Neurology University of Texas, Health Sciences Center at Houston Synopsis: Intravenous immunoglobulin (IVIg) is now the first-line therapy for Guillain-Barré syndrome (GBS). However, there are many disadvantages including high cost, supply shortages, and multiple side effects…Read More about 2017 GBS|CIDP Foundation Grant Awardees